Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals
Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects
Ligand Provides Highlights from Today’s Analyst Day Event
Ligand Reports Third Quarter 2017 Financial Results
Reminder: Ligand to Host Analyst Day on November 14th in New York City
Ligand to Participate in the Stephens Fall Investment Conference
Ligand to Report Third Quarter 2017 Results on November 9th
Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments
Ligand to Host Analyst Day on November 14th in New York City
Ligand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Appoints Dr. Nancy Gray to its Board of Directors
Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology
Ligand Reports Second Quarter 2017 Financial Results
